RECEIVED
CENTRAL FAX CENTER
JUL 25 2007

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Presently Amended) A method for draining fluid from the posterior chamber of the eye of a human or veterinary patient, said method comprising the step of:

A. creating a passageway between the posterior chamber of the eye and either i) a location within the optic nerve or ii) a location within the subarachnoid space, said passageway comprising an opening in the lamina cribosa.

2. (Original) A method according to Claim 1 wherein Step A is carried out by implanting a tubular shunt such that fluid from the interior of the eye will enter one end of the shunt and said fluid will exit the other end of the shunt either i) at a location within the optic nerve or ii) at a location within the subarachnoid space.

3. (Original) A method according to Claim 2 wherein the shunt comprises a tube having a proximal end, a distal end and least one tissue engaging member formed on the shunt to deter unwanted movement of the shunt after it has been implanted.

4. (Original) A method according to Claim 3 wherein the at least one tissue engaging member comprises a barb or barb like structure that allows the shunt to be advanced through tissue in a distal direction but engages the tissue in a manner that deters subsequent retraction of the shunt in a proximal direction.

5. (Original) A method according to Claim 2 wherein the shunt comprises a tube having a proximal end, a distal end and a flange member formed on the proximal end thereof.

PAGE 3/10 * RCVD AT 7/25/2007 8:55:50 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/13 * DNIS:2738300 * CSID:+949 450 1764 * DURATION (mm-ss):02-54

6. (Original) A method according to Claim 2 wherein the shunt comprises a tube having a valve associated therewith, said valve being operative to perform at least one valving function selected from the group consisting of a) allowing fluid to flow out of the eye but deterring fluid form backflowing into the eye and b) allowing fluid to flow out of the eye only when the fluid pressure exceeds a predetermined maximum pressure.

7. (Original) A method according to Claim 2 wherein the shunt comprises a tube having a proximal end, a distal end and at least one shielding member associated therewith to deter foreign matter or cells from clogging the tube.

8. (Original) A method according to Claim 7 wherein the shielding member comprises a semi-permeable membrane constructed and positioned such that fluid flowing out of the distal end of the tube will diffuse outwardly through the membrane but foreign matter and cells will not diffuse inwardly through the membrane and into the distal end of the tube.

9. (Cancelled)

10. (Original) A method according to Claim 2 wherein the shunt comprises a tube having a distal tip that is configured to penetrate through tissue.

11. (Original) A method according to Claim 1 wherein the method further comprises the performance of a vitrectomy procedure prior to, concurrently with or after the performance of Step A.

PAGE 4/10 * RCVD AT 7/25/2007 8:55:50 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/13 * DNIS:2738300 * CSID:+949 450 1764 * DURATION (mm-ss):02-54

12. (Presently Amended) A method for draining fluid from the posterior chamber of the eye of a human or veterinary patient, said method comprising the step of:

A. creating a passageway between the posterior chamber of the eye and either i) a location within the optic nerve or ii) a location within the subarachnoid space; ~~according to Claim 1~~

wherein the method further comprises liquefaction of at least a portion of the vitreous humor prior to, concurrently with or after the performance of Step A.

13. (Original) A method according to Claim 12 wherein liquefaction of at least a portion of the vitreous humor is accomplished by administering to the patient a therapeutically effective amount of an agent that causes vitreal liquefaction.

14. (Original) A method according to Claim 13 wherein the agent that causes vitreal liquefaction is selected from the group consisting of:

urea;

urea derivatives;

compounds having urea groups;

hyaluronidase; and

other enzymes that cause vitreal liquefaction.

15. (Presently Amended) A method ~~according to Claim 2~~ for draining fluid from the posterior chamber of the eye of a human or veterinary patient, said method comprising the step of:

A. creating a passageway between the posterior chamber of the eye and either i) a location within the optic nerve or ii) a location within the subarachnoid space by implanting a tubular shunt such that fluid from the interior of the eye will enter one end

PAGE 5/10 * RCVD AT 7/25/2007 8:55:50 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/13 * DNIS:2738300 * CSID:+949 450 1764 * DURATION (mm-ss):02-54

of the shunt and said fluid will exit the other end of the shunt either at a location within the optic nerve or at a location within the subarachnoid space; wherein the step of implanting the shunt comprises ~~Step A further comprises:~~forming an opening in the pars plana [[;]] and advancing the shunt through the pars plana opening, through the posterior chamber of the eye and into the optic nerve or lamina cribosa.

16. (Original) A method according to Claim 15 wherein the shunt has a proximal opening, a distal opening and a lumen and wherein the shunt is advanced to a location where its proximal opening is positioned so as to receive fluid from the posterior chamber of the eye and its distal opening is positioned to allow said fluid to drain into the optic nerve or subarachnoid space.

17. (Presently Amended) A method ~~according to Claim 2~~ for draining fluid from the posterior chamber of the eye of a human or veterinary patient, said method comprising the step of:

A. creating a passageway between the posterior chamber of the eye and either i) a location within the optic nerve or ii) a location within the subarachnoid space by implanting a tubular shunt such that fluid from the interior of the eye will enter one end of the shunt and said fluid will exit the other end of the shunt either at a location within the optic nerve or at a location within the subarachnoid space;

wherein the shunt is initially positioned within a cannula that has an open distal end and wherein the step of implanting the shunt ~~Step A~~ comprises:

inserting the cannula into the eye;

positioning the distal end of the canula adjacent to the lamina cribosa;

advancing the shunt from the cannula into the optic nerve; and

removing the cannula while leaving the shunt implanted within the eye such that the shunt will drain fluid from the posterior chamber of the eye into either the optic nerve or the subarachnoid space.

PAGE 6/10 * RCVD AT 7/25/2007 8:55:50 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/13 * DNIS:2738300 * CSID:+949 450 1764 * DURATION (mm-ss):02-54

18. (Original) A method according to Claim 17 wherein a pusher is positioned in the cannula behind the shunt and wherein the step of advancing the shunt from the cannula into the optic nerve comprises advancing the pusher so as to push the shunt out of the open distal end of the cannula.

19. (Original) A method according to Claim 2 wherein the shunt device is configured to extend through the vitreous body such that aqueous humor will drain through the shunt and into either the optic nerve or the subarachnoid space.

20. (Cancelled)

21. (Cancelled)

22. (Withdrawn) A shunt device for draining fluid from the posterior chamber of the eye into the optic nerve or subarachnoid space, said device comprising:

a tube having a proximal end, a distal end and a lumen extending longitudinally therethrough;

a substantially conical tip member on the distal end of the tube;

a plurality of openings formed in the substantially conical tip member to allow fluid to drain out of the lumen of the tube; and

at least one tissue engaging member configured to allow the shunt to be advanced, tip member first, into tissue but to engage said tissue in such a manner as to subsequently deter retraction of the shunt out of the tissue.

PAGE 7/10 * RCVD AT 7/25/2007 8:55:50 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/13 * DNIS:2738300 * CSID:+949 450 1764 * DURATION (mm-ss):02-54

23. (Withdrawn) A shunt device according to Claim 22 further comprising a one way valve that allows fluid to flow in only one direction through the lumen of the tube.

24. (Withdrawn) A shunt device according to Claim 22 further comprising a shielding member which deters foreign matter or cells from clogging the tube.

25. (Withdrawn) A shunt device according to Claim 24 wherein the shielding member comprises a semi-permeable membrane constructed and positioned such that fluid flowing out of the openings formed in the tip member will diffuse outwardly through the membrane but foreign matter and cells will not diffuse inwardly through the membrane and into the lumen of the tube.

26. (Withdrawn) A shunt device according to Claim 22 further comprising a flange member on the proximal end of the tube.

27. (Withdrawn) A shunt device according to Claim 22 that is at least partially formed of material selected from the group consisting of:

silicon;

polyethylene;

polypropylene;

polycarbonate;

stainless steel; and

other biologically compatible material.

PAGE 8/10 * RCVD AT 7/25/2007 8:55:50 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/13 * DNIS:2738300 * CSID:+949 450 1764 * DURATION (mm-ss):02-54

28. (Withdrawn) A shunt device according to Claim 22 wherein the tube is configured to extend through the vitreous body, thereby providing for drainage of aqueous humor through the vireous body and into either the optic nerve or the subarachnoid space.

29. (Withdrawn) A shunt device according to Claim 22 wherein the tube is configured to extend through a subconjunctival or subscleral tunnel, thereby bypassing the posterior chamber and vireous cavity.

30. (Withdrawn) A system comprising a shunt device according to Claim 22 in combination with a cannula, said shunt device being initially positioned within the cannula and subsequently advanceable out of the cannula.

31. (Withdrawn) A system according to Claim 30 further comprising a pusher that is insertable into the cannula to push the shunt device out of the cannula.

PAGE 9/10 * RCVD AT 7/25/2007 8:55:50 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/13 * DNIS:2738300 * CSID:+949 450 1764 * DURATION (mm-ss):02-54